A Phase 1/2 interventional study of Investigational Influenza Vaccine and COVID-19 Vaccine in Influenza,Human and COVID-19, sponsored by BioNTech SE. Completed at 22 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by BioNTech SE · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 966 studies in Influenza, Human with a site in United States — 60 open to participants now, 85 under way, 7 of them phase 3. Influenza, Human · United States.
Among the 966 studies in Influenza, Human with a site in United States, this one is the 169th largest by enrollment of the 843 interventional ones that give a count, is one of 35 that started in 2024, is one of 72 in phase 1/2, and was the 907th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →60 of the 966 studies in Influenza, Human with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
David Moss · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
966 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 249 · Phase 2 244 · Phase 3 127 · Phase 4 147
First in 1997; this study’s year is marked. 35 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,353 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 270 across the 843 interventional studies, 261 across the 122 observational. Of the 841 that completed or were terminated, 433 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
435 of 966 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
BioNTech SE has 5 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
41 of the studies in Influenza, Human with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496450Phase 3ModernaTX, Inc.A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | 2027-01-28 |
| NCT06094010Phase 3Hoffmann-La RocheA Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | 2027-05-11 |
| NCT07159763Phase 3Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | 2027-07-02 |
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 41 to your calendar (.ics) → With an account.
Among the 966 studies in Influenza, Human with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Please refer to the study contact for further eligibility details.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low Dose COVID-19 Vaccine and Placebo
Biological: COVID-19 Vaccine · Other: Placebo
Medium Dose COVID-19 Vaccine and Placebo
Biological: COVID-19 Vaccine · Other: Placebo
High Dose COVID-19 Vaccine and Placebo
Biological: COVID-19 Vaccine · Other: Placebo
Low Dose Investigational Influenza Vaccine and Placebo
Biological: Investigational Influenza Vaccine · Other: Placebo
Licensed Influenza Vaccine 1 and Licensed COVID-19 Vaccine
Biological: COVID-19 Vaccine · Biological: Licensed Influenza Vaccine 1
Licensed Influenza Vaccine 2 and Licensed COVID-19 Vaccine
Biological: COVID-19 Vaccine · Biological: Licensed Influenza Vaccine 2
Medium Dose Investigational Influenza Vaccine and Placebo
Biological: Investigational Influenza Vaccine · Other: Placebo
Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo
Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo
Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine and Placebo
Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo
Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo
Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo
High Dose Investigational Influenza Vaccine and Placebo
Biological: Investigational Influenza Vaccine · Other: Placebo
Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo
Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo
Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo
Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo
High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine and Placebo
Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo
High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine and Placebo
Combination Product: Investigational Influenza/COVID-19 Vaccine · Other: Placebo
Investigational Influenza Vaccine
Pfizer-BioNTech COVID-19 Vaccine
Combined investigational influenza and Pfizer-BioNTech COVID-19 Vaccine
Licensed Influenza Vaccine 1
Licensed Influenza Vaccine 2
Saline
Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination
Local reactions included redness, swelling, and pain at the injection site, were recorded in the electronic dairy (e-diary) or case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol. Percentage of participants with at least 1 local reaction of grade 1 and above were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
Cohort 2: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination
Local reactions included redness, swelling, and pain at the injection site, were recorded in the e-diary or CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol. Percentage of participants with at least 1 local reaction of grade 1 and above were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
Cohort 1: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination
Systemic Events: fever, diarrhea, vomiting, headache, fatigue/tiredness, chills, new or worsened muscle pain, and new or worsened joint pain, were recorded in the e-diary or CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol. Percentage of participants with at least 1 systemic event of grade 1 and above were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
Cohort 2: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination
Systemic Events: fever, diarrhea, vomiting, headache, fatigue/tiredness, chills, new or worsened muscle pain, and new or worsened joint pain, were recorded in the e-diary or CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol. Percentage of participants with at least 1 systemic event of grade 1 and above were reported in this outcome measure.
Time frame: From Day 1 through Day 7 after Vaccination [Vaccination on Day 1]
Cohort 1: Percentage of Participants Reporting Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious AEs. Serious AE (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
Time frame: From Vaccination on Day 1 through 1 month after Vaccination [Vaccination on Day 1]
Cohort 2: Percentage of Participants Reporting AEs From Vaccination Through 1 Month After Vaccination
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious AEs. SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
Time frame: From Vaccination on Day 1 through 1 month after Vaccination [Vaccination on Day 1]
Cohort 1: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination
SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, and any other pre-specified criteria in protocol of the study or other important medical event. Only SAEs collected by non-systematic assessment (excluding local reactions and systematic events \[if any\]) were included in this outcome measure.
Time frame: From Vaccination on Day 1 through 6 Months after Vaccination [Vaccination on Day 1]
Cohort 2: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination
SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, and any other pre-specified criteria in protocol of the study or other important medical event. Only SAEs collected by non-systematic assessment (excluding local reactions and systematic events \[if any\]) were included in this outcome measure.
Time frame: From Vaccination on Day 1 through 6 Months after Vaccination [Vaccination on Day 1]
There were 2 cohorts in the study: Cohort 1 enrolled participants 18 to 64 years of age and Cohort 2 enrolled participants \>=65 years of age.
| Milestone | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 51 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 51 | 50 | 50 | 50 | 50 | 50 | 50 | 51 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
| Vaccinated | 51 | 50 | 49 | 50 | 50 | 50 | 50 | 50 | 49 | 49 | 51 | 50 | 50 | 50 | 50 | 50 | 49 | 50 | 50 | 50 | 50 | 50 | 49 | 50 | 50 | 50 | 50 |
| Completed | 49 | 49 | 49 | 47 | 48 | 48 | 47 | 48 | 48 | 43 | 50 | 48 | 50 | 45 | 48 | 50 | 48 | 46 | 48 | 49 | 49 | 49 | 47 | 48 | 48 | 49 | 48 |
| Not completed | 2 | 1 | 1 | 3 | 2 | 2 | 3 | 2 | 2 | 7 | 1 | 2 | 0 | 5 | 2 | 0 | 2 | 5 | 2 | 1 | 1 | 1 | 3 | 2 | 2 | 1 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 2 | 1 | 3 | 2 | 0 | 5 | 0 | 2 | 0 | 4 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other: unspecified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Randomized but not vaccinated | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Local reactions included redness, swelling, and pain at the injection site, were recorded in the electronic dairy (e-diary) or case report form (CRF) after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol. Percentage of participants with at least 1 local reaction of grade 1 and above were reported in this outcome measure.
| Percentage of participants | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination | 50.0 (35.5 to 64.5) | 61.2 (46.2 to 74.8) | 65.3 (50.4 to 78.3) | 80.0 (66.3 to 90.0) | 42.0 (28.2 to 56.8) | 70.0 (55.4 to 82.1) | 74.0 (59.7 to 85.4) | 72.0 (57.5 to 83.8) | 79.6 (65.7 to 89.8) | 89.6 (77.3 to 96.5) | 78.4 (64.7 to 88.7) | 86.0 (73.3 to 94.2) | 69.4 (54.6 to 81.7) | 90.0 (78.2 to 96.7) |
Local reactions included redness, swelling, and pain at the injection site, were recorded in the e-diary or CRF after vaccination. Local reactions were graded per the 'Local Reaction Grading Scale' per protocol. Percentage of participants with at least 1 local reaction of grade 1 and above were reported in this outcome measure.
| Percentage of participants | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 2: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination | 30.0 (17.9 to 44.6) | 42.0 (28.2 to 56.8) | 42.9 (28.8 to 57.8) | 64.0 (49.2 to 77.1) | 36.7 (23.4 to 51.7) | 58.0 (43.2 to 71.8) | 66.0 (51.2 to 78.8) | 63.3 (48.3 to 76.6) | 66.7 (51.6 to 79.6) | 60.0 (45.2 to 73.6) | 68.0 (53.3 to 80.5) | 60.0 (45.2 to 73.6) | 67.3 (52.5 to 80.1) |
Systemic Events: fever, diarrhea, vomiting, headache, fatigue/tiredness, chills, new or worsened muscle pain, and new or worsened joint pain, were recorded in the e-diary or CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol. Percentage of participants with at least 1 systemic event of grade 1 and above were reported in this outcome measure.
| Percentage of participants | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 1: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination | 64.0 (49.2 to 77.1) | 57.1 (42.2 to 71.2) | 49.0 (34.4 to 63.7) | 72.0 (57.5 to 83.8) | 44.0 (30.0 to 58.7) | 68.0 (53.3 to 80.5) | 68.0 (53.3 to 80.5) | 68.0 (53.3 to 80.5) | 77.6 (63.4 to 88.2) | 70.8 (55.9 to 83.0) | 70.6 (56.2 to 82.5) | 78.0 (64.0 to 88.5) | 73.5 (58.9 to 85.1) | 76.0 (61.8 to 86.9) |
Systemic Events: fever, diarrhea, vomiting, headache, fatigue/tiredness, chills, new or worsened muscle pain, and new or worsened joint pain, were recorded in the e-diary or CRF after vaccination. Systemic events were graded per the 'Systemic Events Grading Scale' per protocol. Percentage of participants with at least 1 systemic event of grade 1 and above were reported in this outcome measure.
| Percentage of participants | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 2: Percentage of Participants With Any Systemic Events for up to 7 Days Following Vaccination | 34.0 (21.2 to 48.8) | 38.0 (24.7 to 52.8) | 40.8 (27.0 to 55.8) | 62.0 (47.2 to 75.3) | 40.8 (27.0 to 55.8) | 36.0 (22.9 to 50.8) | 62.0 (47.2 to 75.3) | 49.0 (34.4 to 63.7) | 56.3 (41.2 to 70.5) | 46.0 (31.8 to 60.7) | 56.0 (41.3 to 70.0) | 46.0 (31.8 to 60.7) | 57.1 (42.2 to 71.2) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious AEs. Serious AE (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
| Percentage of participants | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 1: Percentage of Participants Reporting Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination | 3.9 (0.5 to 13.5) | 2.0 (0.1 to 10.6) | 6.1 (1.3 to 16.9) | 2.0 (0.1 to 10.6) | 10.0 (3.3 to 21.8) | 4.0 (0.5 to 13.7) | 8.0 (2.2 to 19.2) | 2.0 (0.1 to 10.6) | 10.2 (3.4 to 22.2) | 10.2 (3.4 to 22.2) | 5.9 (1.2 to 16.2) | 6.0 (1.3 to 16.5) | 8.0 (2.2 to 19.2) | 6.0 (1.3 to 16.5) |
An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious AEs. SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
| Percentage of participants | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 2: Percentage of Participants Reporting AEs From Vaccination Through 1 Month After Vaccination | 8.0 (2.2 to 19.2) | 12.0 (4.5 to 24.3) | 12.2 (4.6 to 24.8) | 2.0 (0.1 to 10.6) | 6.0 (1.3 to 16.5) | 4.0 (0.5 to 13.7) | 6.0 (1.3 to 16.5) | 8.0 (2.2 to 19.2) | 4.1 (0.5 to 14.0) | 2.0 (0.1 to 10.6) | 4.0 (0.5 to 13.7) | 12.0 (4.5 to 24.3) | 8.0 (2.2 to 19.2) |
SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, and any other pre-specified criteria in protocol of the study or other important medical event. Only SAEs collected by non-systematic assessment (excluding local reactions and systematic events \[if any\]) were included in this outcome measure.
| Percentage of participants | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 1: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination | 0 (0.0 to 7.0) | 2.0 (0.1 to 10.6) | 0 (0.0 to 7.3) | 2.0 (0.1 to 10.6) | 0 (0.0 to 7.1) | 0 (0.0 to 7.1) | 0 (0.0 to 7.1) | 0 (0.0 to 7.1) | 2.0 (0.1 to 10.9) | 0 (0.0 to 7.3) | 0 (0.0 to 7.0) | 0 (0.0 to 7.1) | 0 (0.0 to 7.1) | 2.0 (0.1 to 10.6) |
SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria - resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, and any other pre-specified criteria in protocol of the study or other important medical event. Only SAEs collected by non-systematic assessment (excluding local reactions and systematic events \[if any\]) were included in this outcome measure.
| Percentage of participants | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cohort 2: Percentage of Participants Reporting SAEs From Vaccination Through 6 Months After Vaccination | 0 (0.0 to 7.1) | 0 (0.0 to 7.1) | 6.1 (1.3 to 16.9) | 4.0 (0.5 to 13.7) | 0 (0.0 to 7.1) | 2.0 (0.1 to 10.6) | 2.0 (0.1 to 10.6) | 0 (0.0 to 7.1) | 2.0 (0.1 to 10.9) | 2.0 (0.1 to 10.6) | 0 (0.0 to 7.1) | 0 (0.0 to 7.1) | 0 (0.0 to 7.1) |
Collected over Systematic assessment: Local reactions and systemic events were assessed from Vaccination on Day 1 to Day 7 after Vaccination; Non-systematic assessment: SAEs were assessed from Vaccination on Day 1 up to 6 months after Vaccination; other AEs were assessed from Vaccination on Day 1 up to 1 month after Vaccination; all-cause mortality: from Vaccination on Day 1 up to 6 months after Vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | 0/51 (0%) | 0/51 (0%) | 34/51 (66.7%) |
| Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 1/50 (2%) | 35/50 (70%) |
| Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | 0/49 (0%) | 0/49 (0%) | 33/49 (67.3%) |
| Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | 0/50 (0%) | 1/50 (2%) | 43/50 (86%) |
| Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine | 0/50 (0%) | 0/50 (0%) | 26/50 (52%) |
| Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 39/50 (78%) |
| Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 41/50 (82%) |
| Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 40/50 (80%) |
| Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | 0/49 (0%) | 1/49 (2%) | 42/49 (85.7%) |
| Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | 0/49 (0%) | 0/49 (0%) | 45/49 (91.8%) |
| Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | 0/51 (0%) | 0/51 (0%) | 40/51 (78.4%) |
| Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 45/50 (90%) |
| Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 40/50 (80%) |
| Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 1/50 (2%) | 45/50 (90%) |
| Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 25/50 (50%) |
| Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 31/50 (62%) |
| Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | 0/49 (0%) | 3/49 (6.1%) | 29/49 (59.2%) |
| Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | 1/50 (2%) | 2/50 (4%) | 37/50 (74%) |
| Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | 0/50 (0%) | 0/50 (0%) | 29/50 (58%) |
| Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | 0/50 (0%) | 1/50 (2%) | 33/50 (66%) |
| Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 1/50 (2%) | 38/50 (76%) |
| Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 35/50 (70%) |
| Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | 0/49 (0%) | 1/49 (2%) | 39/49 (79.6%) |
| Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | 1/50 (2%) | 1/50 (2%) | 35/50 (70%) |
| Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | 0/50 (0%) | 0/50 (0%) | 39/50 (78%) |
| Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 30/50 (60%) |
| Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | 0/50 (0%) | 0/50 (0%) | 36/50 (72%) |
| Event | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| BacteraemiaInfections and infestations | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| Escherichia pyelonephritisInfections and infestations | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| PneumoniaInfections and infestations | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| SepsisInfections and infestations | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| Lumbar radiculopathyNervous system disorders | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| Acute kidney injuryRenal and urinary disorders | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| Coronary artery diseaseCardiac disorders | 0/51 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/51 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 1/50 | 0/50 | 0/50 | 0/49 | 0/50 | 0/50 | 0/50 | 0/50 |
| Event | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1 + Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN)General disorders | 25/51 | 30/50 | 32/49 | 40/50 | 20/50 | 35/50 | 36/50 | 36/50 | 39/49 | 43/49 | 40/51 | 43/50 | 34/50 | 44/50 | 15/50 | 21/50 | 20/49 | 31/50 | 16/50 | 28/50 | 33/50 | 29/50 | 30/49 | 30/50 | 33/50 | 29/50 | 33/50 |
| Fatigue (FATIGUE)General disorders | 24/51 | 22/50 | 19/49 | 30/50 | 18/50 | 28/50 | 29/50 | 27/50 | 37/49 | 29/49 | 29/51 | 36/50 | 28/50 | 33/50 | 10/50 | 8/50 | 7/49 | 22/50 | 13/50 | 13/50 | 19/50 | 18/50 | 21/49 | 10/50 | 23/50 | 14/50 | 19/50 |
| Headache (HEADACHE)Nervous system disorders | 22/51 | 17/50 | 13/49 | 25/50 | 12/50 | 20/50 | 22/50 | 21/50 | 25/49 | 21/49 | 26/51 | 28/50 | 20/50 | 25/50 | 7/50 | 11/50 | 11/49 | 12/50 | 14/50 | 12/50 | 17/50 | 10/50 | 12/49 | 11/50 | 12/50 | 14/50 | 18/50 |
| Chills (CHILLS)General disorders | 7/51 | 7/50 | 7/49 | 14/50 | 9/50 | 19/50 | 23/50 | 16/50 | 19/49 | 23/49 | 17/51 | 24/50 | 19/50 | 24/50 | 5/50 | 4/50 | 2/49 | 9/50 | 4/50 | 10/50 | 12/50 | 8/50 | 9/49 | 6/50 | 11/50 | 10/50 | 12/50 |
| Myalgia (MUSCLEPAIN)Musculoskeletal and connective tissue disorders | 10/51 | 9/50 | 6/49 | 18/50 | 7/50 | 15/50 | 18/50 | 10/50 | 21/49 | 13/49 | 19/51 | 18/50 | 16/50 | 19/50 | 6/50 | 7/50 | 7/49 | 6/50 | 6/50 | 9/50 | 14/50 | 6/50 | 10/49 | 11/50 | 14/50 | 12/50 | 14/50 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 4/51 | 4/50 | 7/49 | 13/50 | 5/50 | 10/50 | 13/50 | 4/50 | 10/49 | 9/49 | 14/51 | 12/50 | 9/50 | 13/50 | 5/50 | 7/50 | 5/49 | 5/50 | 4/50 | 6/50 | 9/50 | 3/50 | 4/49 | 6/50 | 7/50 | 6/50 | 9/50 |
| Injection site swelling (SWELLING)General disorders | 3/51 | 2/50 | 1/49 | 2/50 | 1/50 | 3/50 | 6/50 | 5/50 | 6/49 | 11/49 | 4/51 | 5/50 | 4/50 | 7/50 | 3/50 | 1/50 | 3/49 | 2/50 | 4/50 | 4/50 | 1/50 | 6/50 | 6/49 | 4/50 | 5/50 | 9/50 | 6/50 |
| Pyrexia (FEVER)General disorders | 1/51 | 1/50 | 1/49 | 1/50 | 1/50 | 5/50 | 3/50 | 4/50 | 9/49 | 3/49 | 6/51 | 5/50 | 9/50 | 8/50 | 2/50 | 1/50 | 1/49 | 3/50 | 0/50 | 2/50 | 3/50 | 1/50 | 1/49 | 0/50 | 5/50 | 2/50 | 4/50 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 6/51 | 7/50 | 3/49 | 3/50 | 5/50 | 3/50 | 8/50 | 8/50 | 7/49 | 6/49 | 4/51 | 6/50 | 5/50 | 4/50 | 5/50 | 2/50 | 2/49 | 2/50 | 5/50 | 3/50 | 0/50 | 4/50 | 7/49 | 1/50 | 2/50 | 6/50 | 4/50 |
| Injection site erythema (REDNESS)General disorders | 1/51 | 5/50 | 0/49 | 2/50 | 2/50 | 3/50 | 3/50 | 5/50 | 2/49 | 6/49 | 4/51 | 7/50 | 4/50 | 7/50 | 1/50 | 1/50 | 1/49 | 4/50 | 3/50 | 3/50 | 0/50 | 1/50 | 2/49 | 4/50 | 5/50 | 7/50 | 4/50 |
Baseline analysis population was evaluated on safety population which included all participants who received any study intervention.
| Age, Customized(Participants) | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1+ Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18-64 years | 51 | 50 | 49 | 50 | 50 | 50 | 50 | 50 | 49 | 49 | 51 | 50 | 50 | 50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 699 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 50 | 49 | 50 | 50 | 50 | 50 | 50 | 49 | 50 | 50 | 50 | 50 | 648 |
| Sex: Female, Male(Participants) | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1+ Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 31 | 25 | 25 | 27 | 29 | 29 | 27 | 29 | 29 | 23 | 34 | 25 | 28 | 31 | 20 | 31 | 31 | 28 | 28 | 21 | 31 | 31 | 23 | 16 | 24 | 32 | 23 | 731 |
| Male | 20 | 25 | 24 | 23 | 21 | 21 | 23 | 21 | 20 | 26 | 17 | 25 | 22 | 19 | 30 | 19 | 18 | 22 | 22 | 29 | 19 | 19 | 26 | 34 | 26 | 18 | 27 | 616 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1+ Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 16 | 14 | 10 | 17 | 12 | 18 | 18 | 14 | 13 | 16 | 11 | 20 | 17 | 20 | 20 | 19 | 17 | 16 | 18 | 19 | 18 | 20 | 22 | 26 | 24 | 24 | 471 |
| Not Hispanic or Latino | 38 | 34 | 35 | 38 | 33 | 37 | 31 | 30 | 35 | 36 | 35 | 39 | 29 | 33 | 30 | 30 | 30 | 32 | 34 | 32 | 31 | 31 | 29 | 28 | 24 | 25 | 25 | 864 |
| Unknown or Not Reported | 1 | 0 | 0 | 2 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 12 |
| Race (NIH/OMB)(Participants) | Cohort 1, Arm A: Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm B: Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm C: High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm D: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm E: Licensed Influenza Vaccine 1+ Licensed COVID-19 Vaccine | Cohort 1, Arm F: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm G: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm H: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm I: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm J: High Dose Investigational Influenza Vaccine + Placebo | Cohort 1, Arm K: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine +Placebo | Cohort 1, Arm L: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm M: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 1, Arm N: High Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm AA: Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm BB: Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm CC: High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm DD: Low Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm EE: Licensed Influenza Vaccine 2 + Licensed COVID-19 Vaccine | Cohort 2, Arm FF: Medium Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm GG: Low Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm HH: Medium Dose Investigational Influenza Vaccine/Low Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm II: Low Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm JJ: High Dose Investigational Influenza Vaccine + Placebo | Cohort 2, Arm KK: Medium Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine+Placebo | Cohort 2, Arm LL: Medium Dose Investigational Influenza Vaccine/High Dose COVID-19 Vaccine + Placebo | Cohort 2, Arm MM: High Dose Investigational Influenza Vaccine/Medium Dose COVID-19 Vaccine + Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Asian | 5 | 4 | 5 | 8 | 1 | 4 | 4 | 4 | 1 | 2 | 6 | 4 | 3 | 3 | 0 | 2 | 1 | 0 | 2 | 0 | 2 | 3 | 2 | 3 | 1 | 1 | 1 | 72 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 3 |
| Black or African American | 12 | 15 | 12 | 11 | 19 | 15 | 12 | 9 | 9 | 13 | 17 | 14 | 14 | 9 | 11 | 13 | 11 | 16 | 6 | 14 | 9 | 10 | 9 | 11 | 7 | 13 | 10 | 321 |
| White | 31 | 30 | 32 | 30 | 29 | 29 | 33 | 35 | 37 | 33 | 27 | 28 | 32 | 38 | 38 | 34 | 37 | 34 | 40 | 35 | 39 | 35 | 37 | 36 | 42 | 34 | 39 | 924 |
| More than one race | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 18 |
| Unknown or Not Reported | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2024 to primary completion in Jul 2025, 8 months.
Results were first posted in Aug 2026, 1 year 1 month after primary completion.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 8 months is below that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.